Best 5 Year Total Return Stocks
« Back to slide 1
Continue to slide 3 »

#9. Lilly (Eli) & Co (LLY) — $10K BECAME $72,697.68

Company Name:  Lilly (Eli) & Co
Sector:  Drugs & Pharmaceuticals
Growth of $10,000.00
With Dividends Reinvested Into LLY

Eli Lilly and Co. is a medicine company. Co. discovers, develops, manufactures and markets products in the human pharmaceutical products segment. Its diabetes, obesity and other cardiometabolic products include Basaglar, Humalog, Mounjaro, Trulicity and Zepbound. Its oncology products include Alimta, Retevmo, Tyvyt and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh and Taltz. Its neuroscience products include Cymbalta and Emgality. Its other products and therapies include Cialis and Forteo. It manufactures and distributes its products through facilities in the U.S. (U.S.), including Puerto Rico, and in Europe and Asia.

« Back to slide 1
Continue to slide 3 »
LLY 5-Year Return
Start date: 12/03/2019
End date: 11/29/2024
Start price/share: $117.61
End price/share: $795.35
Starting shares: 85.03
Ending shares: 90.72
Dividends reinvested/share: $20.00
Total return: 621.51%
Average Annual Total Return: 48.54%
Starting investment: $10,000.00
Ending investment: $72,156.51

Presented with the assumption of reinvestment of any dividends on ex-date; historical stock values are shown adjusted for any subsequent splits.
Investing Slideshows
Wise & Famous Investing Quotes
20 Largest Companies In The USA
26 Growth Stocks For 2026
10 Dividend Leaders Ready To Run
Best 5-Year Total Return Stocks
Best 10-Year Total Return Stocks
Best 2-Decade Total Return Stocks
LLY — Current Quote
Quotes delayed 20 minutes
Get Free SEC filing alerts for LLY:
LLY SEC Filing Email Alerts ServiceExternal link
 

Best 5 Year Total Return Stocks - Page 2 | www.RediNews.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in RediNews.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video.